Argis Pharmaceuticals

Argis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Seoul, South Korea, specializing in the development of innovative treatments for metabolic and inflammatory diseases. The company's lead program, ARG-001, is a selective thyroid hormone receptor beta (THR-beta) agonist designed to treat nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). By targeting the THR-beta pathway, Argis aims to reduce hepatic fat accumulation and inflammation while avoiding the systemic side effects typically associated with THR-alpha activation. The company is leveraging its expertise in small molecule drug discovery to address significant unmet medical needs in the global hepatology and endocrinology markets.